Penney, C. | Search bioRxiv

bioRxiv2026

(E,E)-bisantrene suppresses MYC expression and displays anti-leukemic activity in acute myeloid leukemia

Background: Acute myeloid leukemia (AML) is genetically diverse with a high unmet clinical need for improved treatment options. Dysregulation of the transcription factor MYC plays a central role in AML progression and therapeutic resistance. (E,E)-bisantrene was recently found to inhibit MYC transcription and downstream activity via G-quadruplex DNA stabilization. This study aimed to evaluate the mechanism of action and preclinical activity of (E,E)-bisantrene in AML. Methods: The in vitro and in vivo activity of (E,E)-bisantrene was determined in a variety of AML models (cell lines, xenograft mouse models, and ex vivo human AML mononuclear cells). Transcriptomic, proteomic and phosphoproteomic analyses were performed after treatment with (E,E)-bisantrene. Analyses of -omics data to identify enriched pathways and upstream regulators were performed. Results: (E,E)-bisantrene demonstrated potent anti-proliferative activity across a panel of AML cell lines, inducing apoptosis and reducing S phase proportions. (E,E)-bisantrene significantly prolonged survival in cell- and patient-derived xenograft models of AML. Mechanistically, RNA-seq and proteomic analysis of MOLM13 and MV4-11 cells treated with (E,E)-bisantrene showed significant reductions in the activity of MYC and E2F, together with the cell cycle regulators CDK1/2/4/5. Transcript and protein levels of MYC were reduced in a dose- and time-dependent manner. TP53 and inflammation-associated transcript signatures were also observed. Conclusion: Anti-proliferative activity of (E,E)-bisantrene in preclinical AML models was associated with a downregulation of MYC, CDK1/2/4/5 and E2F. This study supports the ongoing clinical evaluation of (E,E)-bisantrene in AML where MYC is a clinically relevant driver of disease aggressiveness and therapy resistance.

cancer biology↗

bioRxiv2025

Haploinsufficiency of KPNA7 causes otosclerosis, likely due to the release of import inhibition of PTHrP and the reactivation of chondrogenesis in the globuli interossei

Otosclerosis is a genetic bone disorder restricted to the otic capsule and a common cause of conductive hearing loss with both familial and sporadic cases. To date, 14 genomic loci (OTSC) and four underlying OTSC genes (MEPE, SERPINF1, FOXL1, SMARCA4) have been identified in autosomal dominant families. A combined genetic/genomics approach on five affected siblings of Northern European ancestry from the island of Newfoundland, Canada identified a premature stop mutation in Karyopherin subunit 7 (KPNA7, c.49C>T, p.R17X). KPNA7 maps to OTSC2 (7q22.1) and encodes the newest of the seven-member importin- family of nuclear transporters and plays a critical role in early embryonic cleavage events and zygotic genome activation. Previous studies reveal that recessive KPNA7 variants cause skeletal abnormalities, including scoliosis and ocular hypertelorism in two sisters with Partial Corpus Callosum Agenesis-Cerebellar Vermis Hypoplasia With Posterior Fosa Cysts Syndrome and more recently, have been implicated in preimplantation embryo arrest (PREMBA) (OMIM 614107). Interestingly, KPNA7 is also a maternal factor with an exclusively embryonic role and likely inhibits non-classical NLS transport of PTHrP, a known activator of chondrogenesis. We propose that KPNA7 haploinsufficiency causes a failure in nuclear transport inhibition of PTHrP in the quiescent embryonic cells of the globuli interossei in the otic capsule and re-activates chondrogenesis. The KPNA7 discovery provides new insights into the pathogenesis of otosclerosis and potential for targeted therapies. Author SummaryOtosclerosis is a distinctly human genetic bone disorder of the otic capsule and a major cause of progressive hearing loss in young adults, particularly in females. Even though otosclerosis has been recognized as a distinct entity for a long time, both its pathogenesis and restriction to the otic capsule remains a mystery. Here, we use a combined genetic/genomics approach to identify a premature stop mutation in five affected siblings of Northern European ancestry from the island of Newfoundland, Canada. KPNA7 encodes the newest of the seven-member importin- family of nuclear transporters and plays a critical role in early embryonic cleavage events and zygotic genome activation. Based on the unique features of the otic capsule, we hypothesize that the premature stop mutation in KPNA7 leads to haploinsufficiency causing a failure in nuclear transport inhibition of PTHrP and reactivates chondrogenesis in the otherwise quiescent embryonic cells within the otic capsule. The KPNA7 discovery provides new insights into the pathogenesis of otosclerosis and potential for targeted therapies.

genetics↗